Current Report Filing (8-k)
February 28 2017 - 9:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 28, 2017
OPIANT PHARMACEUTICALS, INC.
(
Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or
other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
401 Wilshire Blvd., 12th Floor
Santa Monica, CA
|
|
90401
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
(424) 252-4756
Registrant’s
telephone number, including area code
(Former
name or former address if changed since last report,)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
On February 28, 2017, Opiant Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing that the Company has received supportive feedback from the U.S. Food and Drug Administration
on a proposed development plan for OPNT002, an intranasally-dosed opioid antagonist, for the treatment of Alcohol Use Disorder.
The full text of the press release is filed as Exhibit 99.1
to this Current Report on Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Opiant Pharmaceuticals, Inc. Press Release, dated February
28, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
|
Date: February 28, 2017
|
By:
|
|
/s/
Dr. Roger Crystal
|
|
|
|
Name: Dr. Roger Crystal
|
|
|
|
Title: President and Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024